Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Avelumab, Palbociclib, and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Trial Status: closed to accrual

This phase I trial studies the side effects and best dose of palbociclib, when given together with avelumab and cetuximab, in treating patients with head and neck squamous cell cancer that has come back or spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving avelumab, palbociclib, and cetuximab may work better in treating patients with recurrent or metastatic head and neck squamous cell cancer.